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Conclusion
Introduction and aim
Betrixaban is a novel oral direct factor Xa inhibitor approved by the Food and Drug
Administration for prophylaxis of venous thromboembolism (VTE) in adult patients
hospitalized for an acute illness at risk for thromboembolic complications. As for other
DOACs, assessment of the anticoagulant effect of betrixaban may be useful in some
situations. Also, clinicians need to know how routine coagulation assays are influenced.
The aim of this study is to determine which coagulation assay(s) should be used to assess
the impact of betrixaban on hemostasis and provide laboratory guidance for their
interpretation.
Adapted-chromogenic anti-Xa assays are the most appropriate assays to measure the
pharmacodynamics of betrixaban in a routine setting. Betrixaban significantly affects several
hemostasis diagnostic tests and this must be taken into consideration when requesting and
interpreting such tests.
Methods
Betrixaban was spiked at final concentrations ranging from 0 to 250 ng/mL in platelet-
poor plasma. These concentrations cover the on-therapy range (from ± 9 ng/mL at Ctrough
to ± 122 ng/mL at Cmax for 40 and 120 mg once daily dose, respectively). We tested the
impact of betrixaban on prothrombin time (PT), activated partial thromboplastin time
(aPTT), dilute Russel viper venom time (dRVVT), chromogenic anti-Xa assays, thrombin
generation assay (TGA) and a large panel of hemostasis diagnostic tests using different
reagents from several manufacturers.
Results : Betrixaban influence routine and specific coagulation assays
Impact of betrixaban on PT Impact of betrixaban on aPTT Measurement of betrixaban pharmacodynamics 
with chromogenic anti-Xa assays 
A concentration-dependent prolongation of aPTT, PT and dRVVT is observed. The sensitivity mainly depends on the reagent. FXa chromogenic assays show high sensitivity and a linear
correlation both depending on the reagent and/or the methodology. Several methodologies applicable for other direct factor Xa inhibitors have to be adapted. As for others direct FXa
inhibitors, chromogenic anti-Xa assays are the most sensitive assays for the measurement of betrixaban in a routine setting. However, only two methodologies appear to be adapted to the
low levels of betrixaban observed in pharmacokinetic studies. For others chromogenic assays, procedures need to be adapted to increase the sensitivity. Some parameters of the TGA
(especially peak and mVRI) are very sensitive to the presence of betrixaban but the lack of standardization and its turnaround time reduce its implementation in routine.
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Impact of betrixaban on calibrated automated thrombogram® 
Betrixaban showed a concentration dependent
prolongation of the prothrombin time. The relation was
linear and the 2xCT depended on the reagent. The
2xCT was ranging from 198ng/mL for STA-Neoplastine
R® to 514ng/mL for Dade® Innovin®.
Betrixaban showed a concentration dependent
prolongation of the aPTT. The relation was curvilinear
and the 2xCT depended on the reagent. The 2xCT was
ranging from 257 ng/mL for SynthAfax® to 479 ng/mL
for C.K. Prest®.
There was a concentration-dependent decrease of the
OD/min. Tests with higher baseline OD/min had a wider
range of quantitation compared to those starting at
lower OD/min at baseline.
The most influenced CAT®
parameters are the peak and
the mean velocity rate index.
There is an inter-reagent
variability. Thanks to their low
IC50 for the peak and the mVRI,
the better resolution and their
large range of application, PPP-
Reagent and PPP-Reagent High
seemed to be the best reagents
to monitor patients on
betrixaban. (ETP: Endogenous
Thrombin Potential; IC50: half-
maximum inhibitory
concentration; LT: Lag Time;
mVRI: mean Velocity Rate
Index; TTP: Time to Peak).
mVRI was defined as follow:
(Peak) / (Time to Peak – Lag
Time).
Betrixaban also affect diagnostic tests : for factors of the intrinsic pathway (FVIII, FIX, FXI and FXII), the aPTT-based clotting method showed a mean decrease of ± 5% at 10 ng/mL of
betrixaban, 26% at 50 ng/mL and 58% at 150 ng/mL. The impact was more pronounced for FXI and FVIII. For FV, FVII and FX, a mean decrease of 1% at 10 ng/mL of betrixaban, 9% at
50 ng/mL and 25% at 150 ng/mL was observed, while prothrombin measurement seemed to be less affected (maximal decrease of 6% at 150 ng/mL) (Data not shown).
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STA®-Neoplastine® R (r2= 0.99; 2xCT= 198 ng/mL; CV= 0.6%)
TriniCLOT® PT HTF (r2= 0.99; 2xCT= 491 ng/mL; CV= 0.9%)
TriniCLOT® PT Excel (r2= 0.99; 2xCT= 354 ng/mL; CV= 1%)
TriniCLOT® PT Excel S (r2= 0.99; 2xCT= 210 ng/mL; CV= 0.5%)
RecombiPlasTin 2G® (r2= 0.99; 2xCT= 407 ng/mL; CV= 1.1%)
STA®-Neoplastine® CI+ (r2= 0.99; 2xCT= 276 ng/mL; CV= 0.7%)
Dade® Innovin®  (r2= 0.99; 2xCT= 514 ng/mL; CV= 1%)
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SynthAfax® (r2= 0.99; 2xCT= 257ng/mL; CV= 0.9%)
STA®-PTT Automate (r2= 0.99; 2xCT= NC; CV= 0.6%)
STA®-Cephascreen® (r2= 0.99; 2xCT= NC; CV= 0.4%)
SynthASil® (r2= 1.00; 2xCT= NC; CV= 1.2%)
STA®-C.K. Prest® (r2= 0.99; 2xCT= 479ng/mL; CV= 1%)
Actin® FS (r2= 0.99; 2xCT= 474 ng/mL; CV= 0.9%)
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Technochrom® Anti-Xa High (r2= 0.96; ½xOD/min= 569 ng/mL; CV= 1.3%)
Technochrom® Anti-Xa (r2= 0.99; ½xOD/min= 240 ng/mL; CV= 0.9%)
HemosIL® Liquid Heparin (r2= 0.97; ½xOD/min= 197 ng/mL; CV= 3.1%)
Biophen® Heparin LRT® (r2= 0.99; ½xOD/min= 499 ng/mL; CV= 0.6%)
Biophen® Direct Factor Xa Inhibitors® (r2= 0.98; ½xOD/min= 447 ng/mL; CV= 0.8%)
STA®-Liquid Anti-Xa (r2= 0.99; ½xOD/min= 300 ng/mL; CV= 0.7%)
Biophen® Heparin LRT® Low (r2= 1.00; ½xOD/min= 120 ng/mL; CV= 1.5%)
Biophen® Direct Factor Xa Inhibitors® Low (r2= 0.99; ½xOD/min= 143 ng/mL; CV= 1.5%)
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